A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
A phase 3 trial of Topotecan in small-cell lung cancer, run by GlaxoSmithKline, now recruiting.
Overview
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) is a phase 3 interventional study registered as NCT07099898 by GlaxoSmithKline, with 420 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-05. Interventions recorded: Ris-Rez and Topotecan.
Setting
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase
Phase 3
Sponsor
GlaxoSmithKline
Registry
Enrolled
420
Similar pages
not linked directly; found by shared links- TrialPharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Shares Topotecan, Small-cell lung cancer and the tag pipeline.
- TrialRetinoblastoma Phase II Expanded Access Clinical Trial
Shares Topotecan and the tag pipeline.
- TrialA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares GSK and the tag pipeline.
- TrialFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Shares GSK and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Shares GSK and the tag pipeline.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)